Loading...

TELO TELOMIR PHARMACEUTICALS INC Payment Defaults 8-K Filing

TLMR

TL

TELOMIR PHARMACEUTICALS INC

(TELO)

2025 8-K

FDA Clearance Announcement

Merger Completion

Compliance Update

IND Submission Update

Shareholder Approvals

Breast Cancer Breakthrough

Research Breakthrough

Nasdaq Compliance Notice

Study Results Announced

Executive Compensation Update

Favorable Safety Results

New Cancer Treatment

Director Resignation

Leukemia Treatment Update

Telomir-1 Breakthrough

New Cancer Research

Cancer Drug Progress

Cancer Treatment Breakthrough

Cancer Research Update

New Drug Insights

New Cancer Data

Stock Sale Complete

New Therapy Insights

Product Expansion

Product Expansion

Equity Offerings

Product Expansion

Product Expansion

Product Expansion

Product Expansion

Strategic Alliances

Product Expansion

Management Changes

Equity Offerings

New Product Launches

Product Expansion

Cancer Drug Results

Breakthrough Announcement

Silver Ion Breakthrough

Oxidative Stress Reduction

Breakthrough Results

Lifespan Restoration

Copper-Binding Drug

Accounting Firm Change

Diabetes Treatment Breakthr...

Management Changes

Age Reversal Study

Management Appointment

External Links:

On October 22, 2025, Telomir Pharmaceuticals, Inc. announced new data showing that their compound Telomir-1 is effective in reducing DNA methylation in key cancer-related genes, outperforming conventional chemotherapy and Rapamycin in an aggressive prostate cancer model. This suggests potential benefits of Telomir-1 for cancer treatment, highlighting its unique epigenetic activity.

AI Assistant

TELOMIR PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.